Cemacabtagene ansegedleucel

"The Gene Editing Therapeutics Market is all about developing advanced treatments that can directly change genes to treat or cure diseases. It's like fixing the root cause of a health issue at the DNA level, offering hope for conditions that were once thought to be untreatable. This market is rapidly growing as these innovative therapies become more widely researched and used." BOSTON, Nov. 20, 2024 /PRNewswire/ -- "According to the latest study from BCC Research, the demand for Gene Editing Therapeutics is estimated at $11 million in 2024 and is forecast to grow at a CAGR of 147% to reach $1.0 billion by the end of 2029. This report takes a close look at the current and future possibilities of gene editing treatments and explores the factors that will help or hinder their use. It also examines the competitive landscape, including what therapeutics companies are working on and how they plan to bring new treatments to market. Additionally, it predicts how the market will evolve by 2029 and provides in-depth profiles of key players, including their business focus, financials, and products. Interesting Facts about the Gene Editing Therapeutics Market The gene editing therapeutics market is just getting started, with the first approved treatment, Casgevy, coming to market in the U.K. and U.S. at the end of 2023. This groundbreaking treatment, developed by CRISPR Therapeutics and Vertex, uses CRISPR/Cas9 technology to edit genes. Casgevy's reach is expected to increase as it is set to become available for children between the ages of 5-12. While most new treatments are still in early development, two promising ones are close to a 2029 market launch: NTLA-2001 and cema-cel. There are challenges. Gene therapies are expensive and difficult to manufacture. To address this, some companies are outsourcing production and some are trying to secure government reimbursement for these life-changing treatments for rare diseases. To obtain more insights and information about the gene editing therapeutics market, click here. Factors contributing to this market's growth include: Increasing Prevalence of Chronic Diseases. More and more people are living with long-term health conditions, such as heart disease, diabetes and cancer. This trend is partly due to the world's aging population. In addition, these diseases often require ongoing treatment. Increasing Prevalence of Rare Genetic Disorders. More people are being diagnosed with uncommon, inherited health conditions caused by changes in their genes. As medical knowledge and genetic testing improve, researchers will become better at identifying these rare disorders, leading to more cases being recognized and treated. Precision Medicine.: This is a tailored approach to healthcare that focuses on treating individuals based on their unique genetic makeup, lifestyle, and environment. Instead of a one-size-fits-all method. Precision medicine provides the most effective treatment for each person, ensuring better outcomes by considering what makes each patient unique. Request a Sample Copy of the Gene Editing Therapeutics Market Report Synopsis This report addresses the following questions: What are the projections for the market? The gene editing therapeutics market is estimated at $11 million in 2024 and is forecast to grow at a CAGR of 147% to reach $1.0 billion by the end of 2029. What factors are driving the growth of the market? - Increasing prevalence of chronic diseases and rare genetic disorders. - Need for precision medicine What segments are covered in the market? Because only one product has been approved to date, with other products still under development, the market is segmented only by region. Which region has the highest market share? North America holds the highest share in the market and will continue to do so through the forecast period. Market leaders include: Allogene Therapeutics Beam Therapeutics Caribou Biosciences Inc. Crispr Therapeutics Editas Medicine Intellia Therapeutics Inc. Precision Biosciences Sangamo Therapeutics Vertex Pharmaceuticals Inc. Verve Therapeutics Inc. Vor Bio More related reports: Global Market for Cell and Gene Therapy: The worldwide industry that develops and sells treatments that use cells or genes to repair or replace damaged or diseased cells can be thought of like a repair shop for the body, where cells or genes are used to fix or replace faulty ones, helping to cure diseases and improve health. This market includes companies working on these innovative treatments. Directly Purchase a copy of the report from BCC Research. For further information or to make a purchase, please get in touch with [email protected]. About BCC Research BCC Research market reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help readers make informed business decisions, free of noise and hype. Contact Us Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA Email: [email protected], Phone: +1 781-489-7301 For media inquiries, email [email protected] or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - SOURCE BCC Research LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

日前，Allogene Therapeutics提交了一份SEC监管文件，宣布决定停止其核心管线cemacabtagene ansegedleucel（cema-cel）针对复发或难治性慢性淋巴细胞白血病（CLL）的ALPHA2临床试验的1期研究队列。 这是由于百时美施贵宝（BMS）的Breyanzi获得CLL的监管批准后带来的竞争压力，使得Allogene的cema-cel针对CLL的1期研究患者入组速度放缓，因此Allogene决定削减该项目。 cema-cel是一款CD19 UCAR-T (AlloCAR-T)，是Allogene最核心的管线。 cema-cel主要被开发用于治疗大B细胞淋巴瘤（LBCL），但Allogene也一直在招募CLL患者参加cema-cel的ALPHA2试验。 Allogene报告，“新的代替治疗方案出现”后，入组速度放缓。因此，公司将停止本试验的注册，并将资源重新分配给其他项目。 这是由于百时美施贵宝（BMS）的Breyanzi于今年3月获得美国FDA批准，用于治疗复发/难治性慢性淋巴细胞白血病（R/R CLL）或小淋巴细胞淋巴瘤（SLL）成人患者。这是首款用于复发性或难治性CLL或SLL成人患者的CAR-T细胞疗法。 另外，归因于Breyanzi新适应症CLL/SLL和套细胞淋巴瘤（今年5月获得FDA批准）的获批，Breyanzi今年第三季度细胞治疗的全球销售额为2.24亿美元，增长143%。 事实上，这对于Allogene并不是一个不能接受的事情，同样对于分析师也是如此。 因为，CLL的患者基数很小，大约有40000名患者，终止该适应症的开发对于Allogene的影响并不大。同时，CLL所归属的ALPHA2试验，早在今年初就被Allogene取消了优先级。 事实上，Allogene的重心早就转移到cema-cel用于LBCL一线巩固治疗的ALPHA3上。 Allogene预计将在2026年上半年完成注册，并于2026年之前获得主要EFS数据，可能于2027年提交BLA。 参考资料： 1.https://www.biospace.com/business/allogene-bows-to-bms-in-leukemia-ending-phase-i-car-t-enrollment 2.https://ir.allogene.com/static-files/f2ba012a-dad3-40bc-854d-f39081f7b8bb 3.https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-third-quarter-2024-financial 本周好文推荐 如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·